Dato�f Dr. Nor Shahidah Khairullah is the Chief Executive Officer of the National Institute for Natural Products, Vaccines and Biological (Ninebio Sdn Bhd). She spearheaded the formation of this new Institute which was itemized in the budget stimulus package towards economic sustainability as announced by The Prime Minister. Dato�f Dr. Nor Shahidah has been involved in a number of international trials including herbal therapy for HIV and Hepatitis. She is also currently the Secretary of the National Committee for Herbal Medicine R& D. She is also an active member of the National Committee for Clinical Research as well as the National Ethics Board. She is also the Chief Executive Officer and Research Chairperson of the Malaysian Liver Foundation, a not-for-profit charitable organization dedicated to the prevention, diagnosis and management of patients with chronic liver cancer.

Daniel Adams became CEO of Protein Sciences in 1995. He has previously founded and managed biopharmaceutical companies that have a combined market value of over $10 billion. He co-founded Biogen (OTC-BGEN) and served as its first President and CEO, founded and was CEO of Advanced Genetic Sciences Inc. ("AGS"), and co-founded Plant Genetic Systems in 1982. Dan holds a BA degree in Chemistry from Cornell University and a JD magna cum laude from New York University School of Law.

Martin F. Bachmann obtained his Masters degree in cell biology from the ETH Zürich, Switzerland and received his Ph.D. in Immunology in 1995 from the Institute for Experimental Immunology, Zurich, Switzerland, in the laboratories of Prof. Rolf Zinkernagel and Hans Hengartner. As the CSO of Cytos Biotechnology AG since October 1999, he applied his extensive immunological experience to generate novel types of vaccines, tackling chronic disease such as hypertension, drug addiction or Alzheimer`s disease. His main current research interest is in understanding the rules that govern the induction of protective immune responses and how these insights translate into the development of optimized vaccine strategies. He received the Pfiizer Prize for Immunology (Switzerland), two silver medals of the Swiss federal Insitute of Technology and the Swiss technology award. He has more than 170 publications in peer reviewed journals.

Dr. Becker joined VaxInnate in December 2005 with 15 years of vaccine development and industry experience at Sanofi Pasteur, leaving as a Vice President of Corporate Development. With eight years of business development experience, he has expertise in identifying, assessing, negotiating and managing collaborative product development relationships with large pharmaceuticals, biotechnology companies, academic institutions and government agencies, having secured over 30 technologies and products. Prior to his business responsibilities, Dr. Becker headed the immunology section and a vaccine development project at Sanofi Pasteur. His academic experience included junior facility positions at Loyola University Chicago and University of Illinois Chicago in the field of Immunology. Dr. Becker received his Ph.D. in Microbiology and Immunology from the University of Kansas and his MBA from Columbia University.

Dr. Berglund is currently the CEO of Vaxiva Biosciences KK, a Tokyo-based company that is developing novel adjuvant technologies for the Japanese and Asian vaccine markets. A native of the US, Dr. Berglund has been living and working in Japan since 2004, initially in the licensing and strategic development group of Kyorin Pharmaceuticals, then as Business Development Director of Innovatis Pharma Corp., a specialty pharma company based in Tokyo. Prior to arriving in Japan, Dr. Berglund worked with Trillium Medical Ventures, a biotechnology consulting firm based in New York City. Dr. Berglund has also served as a scientific specialist at Lahive & Cockfield LLP, a law firm in Boston that specializes in IP issues. In 1999, Dr. Berglund received his PhD in Biochemistry from the Johann Wolfgang Goethe-Universität for research on eukaryotic transcriptional mechanisms, work which was completed while working as a scientist at Hoechst-Marion-Roussel (now Sanofi-Aventis) in Frankfurt, Germany. Prior to his doctoral work, Dr. Berglund completed a Masters of Science in Biochemistry at Boston University Medical Center in Boston, Mass.

Dr. Martins joined Dynavax in March 2006 as Vice President, Clinical Development. Eduardo came to us from InterMune, where he was Vice President, Medical Affairs. From 1999 to 2005, Dr. Martins was Vice President, Medical Affairs and Medical Director at SciClone Pharmaceuticals, where he also served as Medical Consultant from 1997 to 1999. He received a Ph.D. in Medicine - Immunology of Liver Diseases from the University of Oxford in 1995 and an M.D. from the Federal University of Rio de Janeiro in 1986.

Chong-Hwan Jonathan Chang, Ph.D currently serves as Executive Vice President and Head of R&D at Green Cross, focusing on the development of various biopharmaceutical products including vaccines. Prior to joining the company, he has held different corporate positions in pharmaceutical companies in the US for the past 14 years. He has extensive knowledge and experience in protein crystallography and drug discovery at DuPont and BMS.

Dr. Chong had spent 15 years at Aventis Pasteur in human vaccine research and development. During his tenure there, Dr. Chong had developed two human vaccines, ProHibit against H. influenzae type b and the component pertussis vaccine, and also took a synthetic peptide-based HIV vaccine to phase I clinical trials in 1994. In 2003, Dr. Chong joined National Health Research Institutes (NHRI) to set up a newly created Vaccine Center for Research and Development. His current research and product development are avian flu inactivated vaccine, enterovirus 71 inactivated vaccines, meningococcal group B subunit vaccine, dengue subunit vaccine and CTL epitopes based HPV vaccines. Dr. Chong�fs laboratory is also currently developing (1) Asian specific reagents for monitoring human cellular immune responses to vaccines, (2) universal carrier proteins for glycoconjugations, and (3) viral vectors for mucosal vaccine delivery. Dr. Chong has authored over 80 original research articles and over 40 patents grants.

Dr.Tawee Chotpitayasunondh is the Associate Professor, Senior Consultant Level 11, of Pediatric Infectious Diseases Specialist at the Queen Sirikit National Institute of Child Health. Having been a pediatric infectious diseases specialist for 30 years eg. TB, HIV/AIDS, Antibiotic, Vaccine, SARS, Avian flu, he had won professional awards - Charles C Shephard Science Award 2000 from US-CDC and Best Research Award 2000 from MOPH,Thailand. He has written 40 scientific publication in many Thai and English Journals and 20 chapters of Pediatric ID in many textbooks.

Dr Supamit supervises the national immunization program (EPI) and heads Poliomyelitis Eradication Coordination office under DDC, MOPH. Trained in medicine, field epidemiology and public health; since 1985 Dr Supamit has served in the technical aspects and coordination of several disease control programs including hepatitis B, dengue, diarrheal diseases, emerging infectious diseases, and EPI. Over twelves years in EPI, he was involved in introductions several new vaccines including hepatitis B, Japanese encephalitis and measles-mumps-rubella vaccines. Now he is also a secretary of the newly established National Vaccine Committee. Since 2003 he has served as a key technical staff for MOPH in the development and coordination of policy and strategies for preparedness and response to emerging infectious diseases including SARS, avian influenza and the threats of pandemic influenza.

As an infectious disease trained, pediatrician and epidemiologist, Dr. Francis has over 30 years experience in epidemic control and vaccines. He spent 21 years working for the U.S. Centers for Disease Control focusing on vaccine-preventable diseases such as measles, cholera, smallpox and hepatitis B. He directed WHO�fs Smallpox Eradication Programme in Sudan and U.P. State in Northern India. His hepatitis B vaccine work included Phase III trials among gay men in the United States (1) and among infants born to carrier mothers in China (2). Dr. Francis was also a member of the WHO team investigating the world�fs first outbreak of Ebola virus. His work in retroviruses began with Dr. Max Essex at Harvard where Dr. Francis received his doctorate.

Professional Experience includes Research Scientist, Division of Epidemic Intelligence Service, Korea National Institute of Health (hereinafter, KNIH), Vice-Director, Division of HIV and TB Control, Korea Center for Disease Control & Prevention (hereinafter, KCDC) and Director, Division of VPD Control & NIP, KCDC (2005 - current ). Research interests includes - HIV Control, Vaccine Preventable Disease Control (TB, Influenza, Measles, Hepatitis B) and Communicable Disease Epidemiology.

Dr. Goldwaser's career in the bio-pharmaceutical industry began over a decade ago, spanning executive and R&D management roles in the biotechnology, chemical and biological drug development markets. Dr. Goldwaser served as CEO of NasVax from its foundation until March 2007. Dr. Goldwaser joined NasVax from Sol-Gel Technologies, where he served as CTO and Chief Biologist and R&D Project Manager overseeing the Company's experiments, worldwide collaborations, IP management, R&D and drug-candidate evaluation. Prior to that, Dr. Goldwaser worked as Lapid Pharmaceuticals' R&D Manager and Supervisor from 1999 through 2002.

Dr Le Van Hiep, Professor, PhD of Medical Microbiology currently serves as Director of Institute of Vaccines and Medical Biologicals (IVAC, Vietnam). He spent 32 years at Vaccine Technology at NIHE (National Institute of Hygiene and Epidemiology) and IVAC. IVAC is the biggest and first quality manufacturer of vaccine and biologicals in Vietnam and accepted by UNICEF in 2007.

Allan Jarvis is currently Senior Vice President, Corporate Development at Aventis Pasteur, a Division of Aventis Pharmaceuticals. In that capacity he is responsible for the Business Development, Strategic Planning and Process Efficiency and Cost Effectiveness functions. He oversees AvP�fs worldwide Corporate Development function and is responsible for managing the company�fs growth through alliances, joint-ventures, partnerships, mergers, acquisitions, and the licensing of products and technology. Prior to this, he was Vice President, Business Development and Strategy for the Vaccine Business Unit of Wyeth Pharmaceuticals. Allan received his PhD in Molecular Genetics from the University of California and held NIH Post-Doctoral Fellowships from 1976-1980 at Sloan Kettering Cancer Institute and the Worcester Foundation for Experimental Biology. In 1980, he co-founded Damon Biotech, Inc. where he held diverse positions of increasing responsibility from Manager, Molecular Biology to Vice President, Research and Vice President Business Development. From 1990 to 1992, he worked at Abbott Laboratories, Inc., as Director, Business Development. In 1992 he joined Repligen Corp. in the dual role of Vice President, Business Planning for the parent company and Sr. Vice President, Commercial Development for its wholly owned subsidiary, Amira, Inc. His primary areas of business focus include: strategic planning, valuing products and technology, negotiations and partnership management.

Peter H. Khoury, Ph.D., MBA is the Global Vice President for Baxter Vaccines. He obtained his docterate in Microbiology from Syracuse University in 1991, studying the effects of heat shock proteins on the resistance of bacterial spores. Dr. Khoury also holds a MBA from Cornell University's Johnson Graduate School of Management in marketing and general management. Dr. Khoury�fs current responsibilities in his position as Vice President, Global Marketing for Baxter International (BioScience Division) includes both vaccines sales and marketing for Latin America, North America, Asia, and the Pacific Region, government contracting, and business development.

Joel Kuritsky, M.D. is the Deputy Director of the Pediatric Dengue Vaccine Initiative effective September 18, 2006. He has twenty-five years of public health experience. He retired from the United States Public Health Service at the Centers for Disease Control in July of 2005, after 23 years of service. In his career at CDC, Dr. Kuritsky served as an EIS Officer in Atlanta and the state of Minnesota, was the Deputy and then Director of the Immunization Services Division in the National Immunization Program. From 2001 to 2002 he served as a principle advisor to the Director of the National Immunization Program for Smallpox preparedness. From 2002 to 2005, he was the branch chief and advisor to the director of the Treatment and Care Branch in the Global AIDS Program.

Thomas Lingelbach is COO of Intercell AG, a publicly listed vaccine biotech company based in Vienna (2005, ICLL; Vienna Stock Exchange), and Managing Director of Intercell Biomedical Ltd., Intercell�Ls first GMP manufacturing site in Livingston, Scotland. In his capacity he supports Intercell�Ls further development towards industrialization and commercialization. In his more than seventeen years in the pharma- and vaccines industry, he held a variety of positions of increasing international responsibility; for the last five years, until Chiron�Ls acquisition by Novartis early 2006, serving as Vice President Industrial Operations in Chiron Vaccines' Executive Committee and Managing Director for Chiron-Behring GmbH & Co. KG in Germany. Before joining Intercell in October 2006, he was significantly involved in Novartis�L integration activities acting as General Manager and Managing Director for its German Operations.

Liu Baokui, M.D., the Director of the Department of Manufacturing Coordinate, is in charge of vaccine production and quality management in China National Biotec Group, and the member of Pharmacopoeia Commission of the Peoples�fs Republic of Chian. In 1978 - 1988, worked in the Department of Epidemiology in the National Vaccine & Serum Institute (NVSI) as the Assistant Researcher for the clinical trial of bacteria vaccine. In 1989 - 1991, engaged in bacterial conjugate vaccine development as a Visiting Scientist in the National Institutes of Health in U.S.A. In 1993 - 1998, was the Director of the Department of Bacterial Vaccine at NVSI for the management of bacterial vaccine production. In 1999 -2006, was the vice manager of the Department of Quality Control and Quality Assurance, and the Vice Chief Engineer at Beijing Tiantan Biological Products corporation Ltd.

Dr. Loucq directs the PATH Malaria Vaccine Initiative (MVI), which seeks to accelerate the development of promising malaria vaccines and ensure their availability and use in developing countries. Dr. Loucq has more than 30 years of experience in medicine, pharmaceuticals, vaccines, and global health. He joined MVI in February 2007, serving as Director of Strategy and Operations and as Interim Director until his appointment as MVI Director three months later. His professional experience spans the globe having managed vaccine businesses in China, India, and Thailand and has been involved in most stages of vaccine development. He has worked with large vaccine companies, such as GlaxoSmithKline and Sanofi Pasteur, and biotech companies including Rhein Biotech and Acambis. He has extensive experience partnering with local governments, building public-private partnerships, and setting up local private collaborations.

Adel A. F. Mahmoud, M.D., Ph.D, is at The Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University. He has recently retired as President of Merck Vaccines and member of Management Committee of Merck & Company, Inc. His prior academic services at Case Western Reserve University and University Hospitals of Cleveland spanned 25 years concluding as Chairman of Medicine and Physician-in-Chief from 1987 to 1998. At Merck, Dr. Mahmoud led the effort to develop four new vaccines which have been launched in 2005-2006, including: combination of Measles, Mumps, Rubella and Varicella; Rota Virus; Shingles and Human Papillomavirus. He is an active contributor to scientific literature and authored and edited several textbooks and reports.

Professor Barry J. Marshall is the co-discoverer of the H. pylori organism, a world authority on H.pylori and co-recipient of the Nobel Prize for Physiology or Medicine 2005. The hypothesis that H.pylori is a causative factor of stomach cancer was accepted in 1994 by the World Health Organisation. This work has now been acknowledged as the most significant discovery in the history of gastroenterology and is compared to the development of the polio vaccine and the eradication of smallpox. Professor Marshall is the Chief Scientific Officer and Chief Executive Officer of Ondek. He is also a clinical professor at the University of Western Australia and a practising specialist gastroenterologist.

Jacques-François Martin has spent the essence of his career in the pharmaceutical, biological and life sciences industries. In 1991, Martin set up Parteurop S.A, a biotech consulting company based in Lyon, France. At Parteurop, Martin as Chairman and CEO, helps establish start-up companies by leveraging innovation from French and foreign institutions. From November 1997 to June 2003 he was a member of the Board of the International AIDS Vaccine Initiative (IAVI). From 2000 to January 2005, Martin held the position of President of The Vaccine Fund. He lead the Fund�fs efforts to provide lifesaving vaccines and other immunization program support to low-income countries. In this capacity, he was also a member of the Board of GAVI (Global Alliance for Vaccines and Immunization).

I am working at GCC for 29years. My major is virology. I am interested in the development of virus vaccine field, especially for Influenza, Varicella- zoster and Hepatitis A virus. I am also a charge of production of these vaccines in GCC.

Dr.G.S.Reddy is the Chief General Manager of Indian Immunologicals Limited, a major veterinary and human vaccines manufacturer in India. He obtained basic degree in Veterinary medicine in 1981 from Andhra Pradesh Agricultural University, Hyderabad. He has 25 years of experience in industry, developing veterinary and human biologicals. Experience encompasses Quality, Research and Development, Manufacturing and Regulatory affairs. He is heading the team which is involved in manufacturing of various veterinary biologicals and human vaccines such as recombinant hepatitis B, Measles, DPT, TT, DT and DPTH vaccines. He worked on collaborative vaccine development projects with Georg August University, Gottingen, Germany and Centers for Disease Control and Prevention(CDC), Atlanta, USA. He is co-author of patent on DNA Rabies vaccine. He has published 40 scientific papers in various journals.

Joe Santangelo is a founder, board member and Development Director of SingVax Pte. Ltd (incorporated in 2004), which is a privately held Singapore biotech company focusing on vaccines for human health. His responsibilities at SingVax include management of all development operations as well as defining the corporate product development strategies. Prior to this he served in R&D roles at Microscience Ltd. from its inception as a spin out from Imperial College of Science Technology and Medicine (UK) in 1997. His overall career in microbiology, infectious diseases and fermentation spans more than 25 years. Joe was born, educated and worked in the United States, before moving to South Africa, Germany, the United Kingdom and Singapore. He has worked in both academia and industry, and moved to the biotech sector 10 years ago.

Mr. Sheldon has been President and Chief Executive Officer of Medicago since August 2003. He has over twenty years of experience in the pharmaceutical industry. Before joining the company, Mr. Sheldon was Vice-President, Sales and Marketing, of Shire Biologics. He was responsible for international expansion with European, American and Asian private partnership agreements. He was also responsible for distribution, customer, and maintenance and engineering at the Shire facility. He successfully negotiated the annual and pandemic contract with the federal and provincial governments. From 1998 to 2000, he was Senior Manager of Commercial Operations where successfully managed the approval of a bladder cancer therapeutic vaccine by the FDA.

Kanwarjit Singh was educated in Economics and Business at Oxford University ( MPhil Economics) and MIT ( MBA) and in Medicine at Columbia University (MD). He subsequently practiced medicine before transitioning to the biotech and pharma sectors where he worked as a consultant at McKinsey and Company and in roles of increasing responsibility in product development and commercialization and strategic planning and business development at Glaxo, Amgen and Bayer. He is now with the Bill and Melinda Gates Foundation where he is with the Business Planning Group working on the Foundation's portfolio of vaccine initiatives. He is a frequent participant in industry symposia and events as a speaker.

Dr. Donata Sizemore joined the Aeras Global TB Vaccine Foundation in 2007 as Senior Director of Vaccine Assessment. She has over 16 years of experience in infectious disease antigen discovery and vaccine development, with 10 years in the biotechnology industry. Prior to joining Aeras, Dr. Sizemore was the Project Manager for Battelle in Columbus, Ohio at the Biomedical Research Center. Among her many responsibilities, she was the Project Manager for a multi-million dollar, multi-task ID/IQ Umbrella Contract for the DMID/NIAID/NIH. Dr. Sizemore is best known for her work in construction and evaluation of bacterial delivery of recombinant proteins and plasmid DNA.

Ih-Jen Su, MD.,PhD. is currently the Director and Distinguished Investigator of the Division of Clinical Research, National Health Research Institutes, Taiwan ( 2002- ), and the jointly appointed Professor of College of Medicine, National Cheng Kung University. His major research interests are in the pathogenesis and therapy of EBV-related lymphoma and HBV-related hepatoma. In the past 10 years, he devoted himself to the control of infections diseases such as influenza, enteroviruses, and tuberculosis in Taiwan. He is the world pioneer scientist in the study of the pathogenesis of virus-associated T cell lymphoma and hemophagocytic syndrome. In recent years, he identified the pre-S mutants as the viral oncoproteins in HBV-related hepatocarcinogenesis. Many of his basic researches now come to the stages of clinical application and targeted therapy such as the application of PPAR agonists and NFkB inhibitors in the therapy of virus-associated cancers. He served as the Board members in many foundations, the editorial board of Cancer Science, and received many prestigious awards in the past years.

Dr Naresh Verma completed his PhD at the Department of Microbiology, University of Sydney in 1988. He has since pursued his research interests in microbial pathogenesis and vaccine development in post-doctoral fellowship appointments at the Karolinska Institute in Sweden and Howard Hughes Medical Institute at Stanford University, U.S.A. He returned to Australia to take up a lectureship at the Australian National University in 1993. He is currently Associate Professor of Microbiology at the School of Biochemistry and Molecular Biology, College of Science, Australian National University. He was awarded the Fellowship of the Australian Society for Microbiology (FASM) in 2005. His main research interests are Bacterial and bacteriophage genetics, and vaccine development.

He took up the current assignment as President and Head of Biopharmaceutical (R&D) at Panacea Biotec Ltd. in 2003 and has been instrumental in setting up a new R&D center for Biopharmaceutical programs of Panacea Biotech in 2005. He has more than 30 years of experience in Research, teaching and scientific administration in relation to medical biotechnology discipline. During his tenure in DBT, New Delhi he was instrumental in designing and implementing medical biotechnology and human genome programs for the country. He has published more than 225 research papers in International and National Medical journal of reputes high impact factors and has got ten National Awards for his Bio medical research activities. These awards have been conferred by Indian Council of Medical Research, Medical Council of India, National Academy of Medical Sciences and other scientific specialty bodies.

Dr. Sy-Dar Wang received his MS and Ph.D. in biochemical engineering from MIT in 1979 and 1988, respectively. He has over 20 years of working experience in the biotechnology/biopharmaceutical industry and is now the Chief Technical Officer and Acting CEO of a human use vaccine development and manufacturer, Adimmune Corporation located in Taiwan, ROC. Before he joined Adimmune Corporation in 2003, he worked for several biotech companies in the United States, including working for Tanox, Inc. as the Director of Manufacturing, working for SAIC Frederick as the Production Manager, as well as working for AMVAX, Inc., Chemgen Corporation, etc. His expertise is in the fermentation and cell culture process development, scale-up and pilot plant operation, GMP facility design, validation, and manufacturing management.

Steve has over 35 years experience in the Biotechnology and the Pharmaceutical industry in Quality Assurance, Manufacturing and Consulting. He has conducted numerous FDA and TGA/PICs compliance audits and gap analysis for many international companies as well as developed multiple training courses for GMP, GLP, Validation, Risk management, HACCP and Medical Devices. He regularly present at conferences and industry seminars on a range of subjects relating to QA, Risk Management and GMP compliance. He also specialise in e-Learning compliance training solutions for intranet delivery within Pharmaceutical companies. Steve has consulted in GMP, GLP and validation since 1989 and has prepared many companies for regulatory in-spections. Steve is a registered auditor for the Australian Pesticides and Veterinary Manufacturing Authority (APVMA) and, in this role, conducts GMP licensing audits on behalf of the Australian government.

Dr. Xiaofeng Liang, serviced the director of National Immunization Programme (NIP), Chinese Center for Disease Control and Prevention today, with the Master Degree in the field of Epidemic & Public Health got from Union Public Health School of Peking Medical University College, China, 1995, and the Post-Doctor experience from Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Miami, Florida, US, 1996.4-1998.4. He is a senior director in the field of vaccine preventable disease prevention and control. He is also a senior scientist in the disease prevention and control, with tens of papers published in the Chinese Journal of Vaccines and Immunization.

Dr. Bing ZENG is Vice President of China National Biotec Group (CNBG) and responsible for international cooperation and business development of CNBG. Prior to joining CNBG in 2004, Dr. ZENG served in various multinational biotech and pharmaceutical companies including Boehringer Mannheim, Organon Teknika (a business unit of AKZO Nobel) and BIOMERIEUX for many years both in China and in Europe. Dr. Bing ZENG received his MBA degree from Nijenrode University (now named NIJENRODE BUSINESS UNIVERSITEIT), The Netherlands Business School in The Netherlands, and his Medical Degree from Beijing Medical University (now named The Medical School of Peking University) in Beijng, China. He practiced in China-Japan Friendship Hospital in Beijing as a Physician before he pursued his career in biotech Industry.

Dr Zhou is the Influenza Coordinator in the World Health Organization (WHO) Regional Office for the Western Pacific in Manila, Philippines with the responsibility of influenza surveillance and control. Before joining WHO, Dr Zhou was a Medical Epidemiologist at the Influenza Division of the US Centers for Disease Control and Prevention. He had more than twenty years of experiences in clinical medicine, biomedical research, and public health services. He was involved in the investigation and control of SARS outbreaks in 2003 and has been working on the surveillance and control of influenza including influenza A/H5N1 in the WHO Western Pacific Region since 2005.